CGP-28014 is a catechol-O-methyltransferase inhibitor potentially for the treatment of Parkinson's disease.Although CGP-28014 increases the renal excretion of both dopamine and dihydroxyphenylacetic acid (DOPAC) it does not affect renal sodium handling indicating a different mechanism of action. CGP-28014 significantly reduced the levels of homovanillic acid (HVA), but did not modify DA and 3,4-dihydroxyphenylacetic acid (DOPAC). References: Kambur O, Talka R, Ansah OB, Kontinen VK, Pertovaara A, Kalso E, Mannisto PT. Inhibitors of catechol-O-methyltransferase sensitize mice to pain. Br J Pharmacol. 2010 Dec;161(7):1553-65. doi: 10.1111/j.1476-5381.2010.00999.x. PubMed PMID: 20726980; PubMed Central PMCID: PMC3010567.

纯度：≥98%

CAS：111757-17-6